Metabolic syndrome is a cluster of metabolic disorders which increases the risk for diabetes and cardiovascular disease. In recent years, research has shown that probiotics may have positive effects on metabolic syndrome components. Although several health-promoting effects of kefir, have been suggested, there is limited evidence for its potential effect on metabolic syndrome. Therefore, it is necessary to clarify the effects of kefir on metabolic disorders including obesity, dyslipidemia, diabetes, and hypertension. To address the research gap, this study aimed to investigate the effects of daily kefir consumption on metabolic syndrome components, inflammatory response and gut microbiota composition in adults with MetS. The study was planned as a randomized, controlled, parallel design and completed with a total of 62 individuals who were diagnosed with metabolic syndrome according to the International Diabetes Federation (IDF) criteria. Participants were randomized into two groups and received daily 180 ml of kefir (n=31) or milk (as control) (n=31) for 12 weeks. Participants were assessed at baseline, week 4, week 8, and week 12 and at all controls dietary records, anthropometric measurements, and blood samples were collected. At baseline and 12th-week fecal samples were also collected in order to analyze gut microbiota composition.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
62
Changes in lipid profile
Measurement of lipid profile (HDL cholesterol, triglyceride levels)
Time frame: baseline, week 4, week 8 and week 12
Changes in glycemic profile
Measurement of fasting glucose, insulin, and calculation of HOMA-IR
Time frame: baseline, week 4, week 8 and week 12
Changes in gut microbiota
Determine the profile of gut flora (% abundance of various bacterial phyla, families, genera and species)
Time frame: week 0- week 12
Changes in Inflammatory Parametres
Measurement of serum cytokines levels (high sensitive serum C- reactive protein ,TNF-α, IL-6, IL-10 ve IFN-γ)
Time frame: baseline and week 12
Changes in serum cholesterol levels
Measurement of total cholesterol and its fractions (mg/dl)
Time frame: baseline, week 4, week 8 and week 12
Changes in triglycerides
Measurement of serum triglyceride (mg/dl)
Time frame: baseline, week 4, week 8 and week 12
Changes in lipoproteins
Measurement of lipoproteins (mg/dl) (apolipoprotein A1, apolipoprotein B, lipoprotein (a))
Time frame: baseline and week 12
Changes in homocysteine
Measurement of homocysteine (umol/L)
Time frame: baseline and week 12
Changes in glycated hemoglobin
Measurement of HbA1c (%)
Time frame: baseline and week 12
Changes in blood pressure
Measurement of systolic and diastolic blood pressure (mm Hg)
Time frame: baseline, week 4, week 8 and week 12
Changes in waist circumference
Measurement of waist circumference (cm)
Time frame: baseline, week 4, week 8 and week 12
Changes in Body Fat
Measurement of % body fat with BIA
Time frame: baseline, week 4, week 8 and week 12
Changes in BMI
weight and height will be measured to report BMI in kg/m2
Time frame: baseline, week 4, week 8 and week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.